I think it relates a lot to what the nature of the biotechnology business is, in particular health biotechnology, which is a long time to fruition, from product to market. The value increment starts very low at the beginning, with a high risk, and it moves through 10 to 15 years to be able to have a highly valuable product on the market. I think that is really where we are for the majority of the companies in Canada; they are SMEs.
